Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Indolent Lymphoma Overview | 10 | 1 |
| Therapeutics Development | 11 | 1 |
| Pipeline Products for Indolent Lymphoma Overview | 11 | 1 |
| Indolent Lymphoma Therapeutics under Development by Companies | 12 | 2 |
| Indolent Lymphoma Pipeline Products Glance | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Indolent Lymphoma Products under Development by Companies | 16 | 2 |
| Indolent Lymphoma Companies Involved in Therapeutics Development | 18 | 23 |
| AbbVie Inc | 18 | 1 |
| Affimed GmbH | 19 | 1 |
| Altor BioScience Corporation | 20 | 1 |
| Amgen Inc. | 21 | 1 |
| Astellas Pharma Inc. | 22 | 1 |
| Bayer AG | 23 | 1 |
| Boehringer Ingelheim GmbH | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| Celgene Corporation | 26 | 1 |
| Eli Lilly and Company | 27 | 1 |
| F. Hoffmann-La Roche Ltd. | 28 | 1 |
| Gilead Sciences, Inc. | 29 | 1 |
| Incyte Corporation | 30 | 1 |
| Infinity Pharmaceuticals, Inc. | 31 | 1 |
| Juno Therapeutics Inc. | 32 | 1 |
| MedImmune, LLC | 33 | 1 |
| Merck &Co., Inc. | 34 | 1 |
| Merck KGaA | 35 | 1 |
| Millennium Pharmaceuticals Inc | 36 | 1 |
| MorphoSys AG | 37 | 1 |
| Novartis AG | 38 | 1 |
| Seattle Genetics, Inc. | 39 | 1 |
| Trillium Therapeutics Inc. | 40 | 1 |
| Indolent Lymphoma Therapeutics Assessment | 41 | 12 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Combination Products | 42 | 1 |
| Assessment by Target | 43 | 3 |
| Assessment by Mechanism of Action | 46 | 3 |
| Assessment by Route of Administration | 49 | 2 |
| Assessment by Molecule Type | 51 | 2 |
| Drug Profiles | 53 | 147 |
| AFM-11 Drug Profile | 53 | 1 |
| ALT-803 Drug Profile | 54 | 3 |
| bendamustine hydrochloride Drug Profile | 57 | 3 |
| BI-836826 Drug Profile | 60 | 1 |
| blinatumomab Drug Profile | 61 | 8 |
| BMS-986016 Drug Profile | 69 | 2 |
| BTH-1677 Drug Profile | 71 | 11 |
| CC-122 Drug Profile | 82 | 2 |
| copanlisib hydrochloride Drug Profile | 84 | 4 |
| DI-B4 Drug Profile | 88 | 1 |
| duvelisib Drug Profile | 89 | 11 |
| entospletinib Drug Profile | 100 | 2 |
| ibrutinib Drug Profile | 102 | 25 |
| INCB-40093 Drug Profile | 127 | 1 |
| INCB-50465 Drug Profile | 128 | 1 |
| inebilizumab Drug Profile | 129 | 2 |
| inebilizumab + MEDI-0680 Drug Profile | 131 | 1 |
| itacitinib adipate Drug Profile | 132 | 3 |
| JCAR-014 Drug Profile | 135 | 3 |
| JCAR-015 Drug Profile | 138 | 5 |
| JCAR-017 Drug Profile | 143 | 3 |
| lenalidomide Drug Profile | 146 | 14 |
| LY-3023414 Drug Profile | 160 | 2 |
| MOR-208 Drug Profile | 162 | 5 |
| obinutuzumab Drug Profile | 167 | 7 |
| ofatumumab Drug Profile | 174 | 8 |
| SEA-CD40 Drug Profile | 182 | 1 |
| TAK-659 Drug Profile | 183 | 1 |
| TTI-621 Drug Profile | 184 | 3 |
| venetoclax Drug Profile | 187 | 9 |
| vorinostat Drug Profile | 196 | 4 |
| Indolent Lymphoma Dormant Projects | 200 | 2 |
| Indolent Lymphoma Discontinued Products | 202 | 1 |
| Indolent Lymphoma Product Development Milestones | 203 | 9 |
| Featured News &Press Releases | 203 | 1 |
| Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society | 203 | 1 |
| Nov 30, 2015: New Data from Bayer s Portfolio in Oncology to be Presented at ASH 2015 | 203 | 1 |
| Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting | 203 | 1 |
| Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG | 204 | 1 |
| Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH | 204 | 2 |
| Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R | 206 | 1 |
| Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting | 207 | 1 |
| Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) | 208 | 2 |
| Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH | 210 | 2 |
| Appendix | 212 | 2 |
| Methodology | 212 | 1 |
| Coverage | 212 | 1 |
| Secondary Research | 212 | 1 |
| Primary Research | 212 | 1 |
| Expert Panel Validation | 212 | 1 |
| Contact Us | 212 | 1 |
| Disclaimer | 213 | 1 |